S1800D Stage IV or Recurrent Non-Small Cell Lung Cancer
What is the Purpose of this Study?
- Be randomly assigned (fair, 50/50 chance) to 1 of 2 groups
-- Group 1 will get the standard of care drugs for NSCLC (docetaxel, gemcitabine, pemetrexed, or ramucirumab combined with docetaxel)
-- Group 2 will get the study drugs
Who Can Participate in this Study?
Patients with NSCLC who:
- Had their cancer progress after their most recent treatment
- Do not use immune-suppressing medications for an organ transplant
For more information about who can join this study, contact the study team at email@example.com.
What is Involved?
We are doing this study to find out if combining two investigational drugs that work with the immune system is a better approach than current therapies for lung cancer. The investigational drugs in this study are N-803 (ALT-803) and pembrolizumab.
versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell
Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy Lung-MAP